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Abstract 
The purpose of this study was to analyze the concept of integration of Intellectual Capital 
and Knowledge Management that can improve and update by the Resource Based Theory 
(RBT) and Knowledge Based Theory (KBT). The research method is qualitative 
interpretive approach and grounded theory research. The study states that the concept of 
integration of IC and KM can improve and update the RBT and KBT as the basic theory of 
IC and KM must be adapted to the conditions of pharmaceutical companies in Indonesia . 
Thus there are changes in the concept of improving and updating RBT and KBT be 
complementary role RBT and KBT . The management model that is used to supplement the 
role of RBT and KBT is a Comprehensive Intellectual Capital Management ( CICM ) 
model because it is very complete and comprehensive as well as an integration or 
combination of IC and KM . 
 
Keywords: Comprehensive Intellectual Capital Management, Resource Based Theory, 
Knowledge Based Theory, Intangible Assets 
 
Introduction 
Intellectual Capital (IC) as intangible asset for the company must be managed and 
enforced well so that it can give benefit on the form of performance improvement, 
competing ability, and welfare of the company. One of the methods that can manage and 
enforce IC is Comprehensive Intellectual Capital Management (CICM) model (Hermawan, 
2015). CICM is a complete and comprehensive management model of IC with three stages, 
they are Knowledge Management (KM), Innovation Management (IM), and Intellectual 
Property Management (IPM) (Al-Ali, 2003). The existing three stages in CICM are valid to 
management and enforcement of three component of IC, namely human capital (HC), 
structural capital (SC), and relational capital (RC). Referring to the research of Hermawan 
(2012), every stage in CICM can produce performance even though the highest 
performance will be gained if the company has been in intellectual property management 
stage or the company has been able to manage the their intellectual wealth. 
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The existence of CICM models have proven that the intangible assets of the 
company made significant contributions to the company, and this is consistent with the 
resource based theory (RBT) and the knowledge based theory (KBT). The essence of both 
theories is that the company will gain a competitive advantage and a superior advantage if 
they manage their assets properly. However, the trends shows that RBT focuses on physical 
assets contributing to organizational performance. In fact, in 1998 alone, IC management 
has contributed approximately 50% - 90% to the value creation of the firm, while 
management of traditional physical assets accounted for only 10% - 50% to the value 
creation by the firm (IFAC, 1998). It means that in this era of nowadays knowledge 
economics, intangible assets play an important role and a greater sustainability for the 
company. In addition, the KBT concept can also improve the company's performance by 
accelerating the flow of knowledge within the company in the form of knowledge transfer 
or knowledge sharing by using SECI (Socialization, Externalization, Combination, 
Internalization) method. This method can also be used to accelerate the flow of knowledge 
and the company's performance on the stage of CICM because at one stage there is phase of 
knowledge management. 
Thus, the three concepts or models (CICM, RBT, and KBT) can be related and 
developed to theoretical concept of CICM model that can complete the role of RBT and 
KBT. Based on those considerations, the objective of this research is to arrange theoretical 
concept review completing the role of RBT and KBT. 
 
Research Model 
This research combines qualitative interpretive research approach or interpretive 
accounting research (IAR) with grounded theory research. The researcher uses IAR in 
accordance to Lukkaa and Modell (2010) and Harris and Durden (2011)’s recommendation. 
They state that IC (or also the flow of this knowledge) is in the domain of management 
accounting research in intellectual resource management field. IC in the domain of 
management accounting is included in the category of non-financial IC and this research 
included in it. Meanwhile, the grounded theory research (Creswell, 2009) is chosen because 
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it is used to formulate a theoretical study that is able to complete the study RBT and KBT 
as the basic theory of IC and KM. 
The focus of the research is to develop a theoretical study that is able to complete 
the RBT and KBT role as the fundamental theory of IC and KM. What is meant by the 
ability to complement the referred role is technically able to operationalize the concept or 
theory of RBT and KBT. Meanwhile, data collection technique in this research is 
conducted in three ways, namely focus group discussion (FGD), documentation and other 
data sources of the process of grounded theory research. For FGD, and documentation 
conducted in March-June 2015. For other sources of data collection process of the process 
of grounded theory research was conducted in July-September 2015. The FGD was 
conducted by involving key informant who chosen through judgment method. FGD was 
conducted on Saturday, 13 June 2015 at in Sri Raras Jati restaurant, Sidoarjo, East Java, 
Indonesia, involving 7 (seven) participants. The goal of FGD was to get more detailed 
information and to conduct an information cross check, including triangulation of data 
sources that have been obtained by previous researchers. Documentation is done by 
searching journals and literature or materials associated with IC and KM as well as the 
pharmaceutical company's business performance. Documentation is mostly done through 
Scopus indexed international journals link, such as the international journal, Intellectual 
Capital. The process of collecting data from the process of grounded theory research is 
done by examining the theories according to IC and KM, namely RBT and KBT. The data 
in the form of theoretical studies and also researches that have been conducted in the 
perspective of RBT and KBT are collected and analyzed. 
Key informants who serve as source of data on the activity of FGD are manager, a 
former supervisor, staff of pharmaceutical companies, the pharmaceutical industry analyst, 
and researcher of IC. The managers of a pharmaceutical company, who were the key 
informants, were the manager of human resource development (HRD), operational 
managers, and marketing managers. The underlying decision why the researchers made the 
managers as key informants was because, according to Hermawan (2013), the parties 
involved in the management of IC is those managers as the implementation of the 
components of HC, SC and RC. While reason of making the former supervisor and staff of 
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pharmaceutical companies as key informant in this research is the need to confirm the 
veracity of the information provided by the managers, who are still active in the 
pharmaceutical company, or in other words, the researcher needed to gain a balance 
information. However, the reason of making the pharmaceutical industry observers as a key 
informant was to provide the latest information about the development of the 
pharmaceutical industry and as judgment information for the information and comments 
provided by other informant. Last, the reason of making IC researcher as a key informant in 
this research is because the researcher needed the comparison between the factual 
information regarding the correlation of practices in the pharmaceutical company with the 
existing theory. Key informant from this IC researcher was also intended to cross check the 
related concepts, research models and as a form of triangulation activity among researchers. 
Key informant determination technique is done with judgment (Marshall, 1996). The 
following data delivers the key informant: 
Table 1. 
Key Informant Data 
No Key Informant Institution Determination Technique 
1 AP PT. PMU Surabaya Judgment 
2 RFA PT. BF Sidoarjo Judgment 
3 DH Pharmaceutical Industry 
Observer 
Judgment 
4 DO Ex Supervisor in PT. “BF” 
Sidoarjo 
Judgment 
5 SRY IC researcher Judgment 
6 WH IC researcher Judgment 
7 STK IC researcher Judgment 
Data Source: FGD 
The validity test of the data in this research is conducted by testing the credibility 
and transferability (Senton, 2004). Credibility test was conducted through triangulation 
tests, namely triangulation of data sources, triangulation of method, and triangulation of 
theory. Transferability test was done by providing the information as complete as possible 
in the research report related to the research process as providence that simplify 
complicated ones. In the qualitative research, researchers could not guarantee the research 
results can be applied to other research, but the task of qualitative research is to explain the 
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research stages and process in detail and clearly so that other qualitative researchers can 
understand it. 
The data analysis included data collection process with data collection stage, data 
reduction, data display, and conclusion (Miles and Huberman, 1984). The data collection 
stage was done by interview and documentation. The collected data is response data of the 
informants through FGD implementation, and documentation such as HC qualification 
required by pharmaceutical company, CPOB determination, and many policies related to 
marketing system in the pharmaceutical company. During this data collection stage, the 
researcher also conducted the data collection and data validity test; they were credibility 
test with triangulation. The triangulation test consists of triangulation test of method, 
triangulation of data resource, and triangulation of theory. 
The data reduction is done by selecting the data that has been collected to look for 
the patterns and the same opinion about the themes of research that has been determined. At 
the stage of data reduction there was a lot of discarded and unused data that was deviating 
from the theme or patterns set in the focus of research. The result of data reduction is data 
display. Based on this data display, the research result started to appear and was able to be 
decomposed into a research report. The last stage of the process of data analysis is the 
conclusion. At this stage researcher continued to conduct the data collection process until 
the data was completely saturated and researchers believed that the results of the study are 
relevant with the purpose and the focus of research. 
In this research, the data analysis was done by testing during research process and 
by coding and development of conceptual categories (Glaser and Strauss, 1967), as it is 
characterized in the grounded theory research. Coding and development of conceptual 
categories are intended to formulate the concept of theoretical study in the domain of 
grounded theory research to complete the role of RBT and KBT as the principle theory of 
IC and KM. 
 
Research Result and Discussion 
To reach the formulation of integration model of IC and KM as new strategy in the 
era of economics science, the researcher performed research activity, namely FGD, 
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documentation, triangulation of method, triangulation of source, and triangulation of 
theory. FGD was applied to key informants who had been determined based on the 
judgment of researcher and also based on the snowball. Documentation was done by 
searching for the data related to the pharmaceutical company in East Java and study theme 
of IC and KM in many relevant internet sites, such as in international journal and accredited 
national journal. Triangulation of method was done during the research by doing cross 
check to the interview result with documentation data and vice versa. Triangulation of 
source was done by doing cross check between the data gained from one key informant to 
another. For triangulation of theory was done by doing cross check between research result 
and used theories, they are the resource based theory (RBT) and the knowledge based 
theory (KBT). 
The use of triangulation of method, triangulation of source, and triangulation of 
theory are intended as credibility test for the data. The data analysis was done by data 
reduction, coding, and data display as well as supported by researcher as research 
instrument, so that the same theme and concept of integration model of IC and KM as new 
strategy and theoretical study of IC and KM that can improve RBT and KBT was gained. 
The following table present the same concept data or pattern as the result of data analysis 
process. 
Table 2 
The Same Concept or Pattern from Coding Process 
Coding Theme or concept 
A The relation between CICM and RBT and KBT as Principle Theory of IC 
and KM 
A. 1. Concept of IC and KM adjusted to the Condition of Pharmaceutical Industry in 
Indonesia 
A2. CICM as Management Model That Can Complement the Role of RBT and KBT 
Source: Data Display of Coding Result and Data Reduction 
Based on the same concept or pattern from coding result, researcher conducted discussion 
of research result by relating between the used theory and phenomena of research result, 
and also with the previous research. 
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A. The Relation between CICM and RBT and KBT as Principle Theory of IC and 
KM 
The referred relation of CICM and RBT and KBT is implementation of CICM 
model if related to RBT and KBT or also CICM model to complement the role of RBT and 
KBT. To reach the stage, this research was analyzed qualitatively regarding the integration 
of IC and KM as they are applied in industry of pharmaceutical company in Indonesia. 
These are the results of study. 
A.1. The Concept of IC and KM Adjusted to the Condition of Pharmaceutical 
Industry in Indonesia 
The initial purpose of this research is to find the theoretical concept that can 
improve RBT and KBT. The words “can improve” means that the role composition of 
tangible assets and this intangible assets is expected to be role by intangible assets. It means 
that this research expected the portion of intangible assets role is more than tangible assets 
either in strategic activity and operational. It is based on the recommendation of Sharabati 
et al (2010), Chen et al (2004), Daum (2005), Boekestein (2006), and Kamath (2008) that 
pharmaceutical company are manufacture company that have solid knowledge with high 
research level and innovation compared to other companies or company type which has 
highly intensive IC, many use much knowledge, and also perform interaction between 
human and technology, as well as dependent on the IC as renewal resources. 
However, according to the research result of FGD, documentation, and research 
process of grounded theory research, it is gained that pharmaceutical industries in Indonesia 
is different from pharmaceutical in foreign countries as recommended by the IC researchers 
as mentioned above. According to key informant, pharmaceutical industries in Indonesia do 
not conduct basic research to produce “patent medicine” as in foreign country so that its 
research activity is neither as much as nor as deep as pharmaceutical companies in foreign 
country. One of the researches done by pharmaceutical company in Indonesia is when they 
give flavor to their medicines, for example orange or strawberry flavor in the children 
medicines. This kind of research makes pharmaceutical companies in Indonesia only 
purchase the non-patent medicine from other countries, so that they do not require 
complicated research. Next, they do conduct many innovations in medicine production, but 
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the innovation is more focused on the marketing activity. Pharmaceutical companies also 
still needed tangible assets in production activity, more over middle and lower 
pharmaceutical company that have no branded product so that the activity is more in 
production. Some pharmaceutical companies even only perform packaging because the 
medicine is already made by the bigger pharmaceutical companies. The summary of 
pharmaceutical industry condition in Indonesia is as follows. 
Table 3 
The Condition of Pharmaceutical Industry in Indonesia 
No The Condition of Pharmaceutical Industry in Indonesia 
1 Do not conduct basic research to find the medicine formulation 
2 Only purchase the off-patent medicine 
3 The performed innovation by adding the certain flavor in the medicine 
4 Still very needed tangible asset for production and operational 
5 In middle and lower pharmaceutical company, the needs of tangible assets is more 
that intangible assets 
6 The small pharmaceutical company only perform the packaging because the 
production is given to the bigger pharmaceutical company, or it is known as 
“maklon” medicine 
Source: Managed Data 
Thus, based on this research, it is shown that the research of OC in pharmaceutical 
companies or industries in Indonesia cannot leave the essence of tangible assets in the form 
of machines, building, equipment, vehicle, and other tangible assets. It means not all 
pharmaceutical company in Indonesia can be called as high IC intensive based company. 
The mapping to pharmaceutical company in Indonesia which is high IC intensive based 
company or not high IC intensive is still needed to be done. Thus, the effort of integration 
of IC and KM to be able to improve RBT and KBT shall consider the condition of 
pharmaceutical industry or company in Indonesia. 
The result of this research is not linear to the initial purpose to improve the RBT 
and KBT because the condition of pharmaceutical industry in Indonesia is different with 
pharmaceutical industry in foreign country as reference of IC researches in foreign country. 
The different research result with initial purpose of the research has been conducted in the 
domain of qualitative research. It is caused by the three conditions of qualitative res2earch 
result, they are the research result is in line with the initial planning, the research result is 
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partially different with the initial planning, and research result is very different with the 
initial planning. Therefore, this research result does not improve RBT and KBT but as a 
complement to the role of RBT and KBT with CICM as management model that can 
complete the role. 
A.2. CICM as the Model that Can Complement the Role of RBT and KBT 
Comprehensive Intellectual Capital Management (CICM) is made as model that can 
improve RBT and KBT because it is very complete and comprehensive in exploring the 
component of IC (HC, SC, RC) and the stages of CICM. As Figure 1, it is explained about 
CICM model. In the figure, there are three stages if CICM, they are 
1. Knowledge management (KM), 
2. Innovation management (IM), 
3. Intellectual property management (IPM). 
 
 
 
 
 
 
 
 
 
 
Figure 1 
CICM MODEL (Modified by Researcher) 
(Source: Al-Ali, 2003:66) 
 
CICM model as in Figure 1 is supported by management goal and purpose for CICM 
illustrating what and how the purpose of the stages of CICM. It is explained in Table 4, as 
follows. 
Table 4 
The Purpose of Management and Purpose for CICM 
 Human Capital Structural 
Capital 
Relational 
Capital 
 
Competitives 
Tools 
 
Maximize Value: IP Management 
Prototypes of 
new product & 
services 
 
Extract Value: Innovation Management 
 
Knowledge & 
Brainpower 
 
Create Value: Knowledge Management 
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CICM Stage IC Group Purpose 
Purpose of 
Management 
Knowledge 
Management 
Material Raw 
Source of 
Knowledge 
Creating Value Recognize and enforce 
the knowledge resource 
required to maintain the 
organizational process 
Innovation 
Management 
Innovation 
Process and 
Resource 
Extraction (Issuing 
Value) 
Release and re-configure 
innovation resource to 
create new ways in 
performing business and 
faster new product 
Intellectual Property 
Management 
Intellectual 
Wealth 
Maximizing Value Allow the use of 
intellectual wealth to 
improve competitive 
position of the company 
and increase the 
organizational income 
Source: Al-Ali (2003:66) 
 
Based on Figure 1 and Table 4 above, it can be known about the purpose of every 
stage of CICM. The first stage is KM which emphasizes more in creating value. The 
concept that can be used in this process is SECI (socialization, Externalization, 
Combination Internalization). The second stage is IM which emphasizes more in extract 
value or produce the values owned by the company. The four strategies that can be used in 
this stage are customer driven (from consumer), inward employee driven (from inside of 
employee themselves), outward employee driven (from outside of employee), and 
technology driven (from technology). Meanwhile, in the third stage, that is IPM which 
more emphasizes in maximize value owned by the company. IPM strategy that can be done 
is brand management (the existence of special work unit handling the brand of the 
company), and IP Portfolio (improve good intellectual property, combine good IP with the 
bad one, eliminate IP which is already gone in the market. 
Meanwhile, this research is qualitative research that will always define something 
contained in the data source, either explicit or implicit. Related to this, the researcher 
conducted data collecting process by FGD and documentation through interpreting process 
of FGD result. During the FGD process, researcher showed some concepts or models such 
as CICM model (Figure 1) and management purpose and purpose for the stages of CICM 
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(Table 4) to key informants. Thus the research result and discussion on this research is 
more related to the interpreting of Figure 1 and Table 4. The research result presentation 
and discussion of every stage of CICM is as follows. 
1. Knowledge Management Stage 
At this stage, the informants agree that the pharmaceutical companies in the stage 
of KM is still restructuring management, recognizing, and trying to use its limited 
resources. Because of the limitations of resources for HC, SC and RC, pharmaceutical 
companies should really be able to utilize their belonging to be empowered its role in 
supporting the company's operations and performance. The way is by KM process. In 
the process of managing knowledge, pharmaceutical companies should be able to 
recognize and use explicit knowledge and tacit/ implied knowledge of the company and 
its employees. Explicit knowledge associated with visible knowledge, such as written 
knowledge, archived and dispersed in the form of books or other printed. Tacit 
knowledge related to invisible knowledge, such as knowledge in the form of know-how, 
experience, skill, and understanding of employees. In the process of this knowledge 
management, small-scale or below the level pharmaceutical company can utilize explicit 
knowledge for various purposes, e.g. for the development of employee skills, to improve 
processes and procedures, as well as the materials to do networking with other parties. 
Pharmaceutical companies can also take advantage of tacit knowledge from the 
employees to be converted into explicit knowledge. The experience and skills of 
employees in the form of tacit knowledge can be transformed into explicit knowledge, 
such as various kinds of rules, procedures operating system, or the working module that 
can improve the performance of employees and the company. 
The use of knowledge can also be done through interaction of IC component. It 
means that knowledge transfer between IC component can be related each other. The 
utilization of knowledge consists of six groups, they are knowledge transfer from HC to 
RC, knowledge transfer from RC to SC, knowledge transfer from SC to HC, knowledge 
transfer from RC to HC, knowledge transfer from SC to RC, and knowledge transfer 
from HC to SC. Table 5 explains about the use of knowledge through interaction of IC 
component. 
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Table 5 
The Use of Knowledge Though Interaction of IC Component 
Knowledge transfer from 
HC to RC 
Knowledge transfer from 
RC to SC 
Knowledge transfer from 
SC to HC 
Employees who had just 
finished a training or 
seminar to give input on 
market orientation or 
changes in consumer 
behavior of pharmaceutical 
products 
The part of marketing 
sharing of experience on 
what is perceived by the 
customer about the quality 
of drugs both from the 
packaging and solubility 
The part of operational or 
production to provides 
information about the new 
rules and regulations that 
exist in the CPOB thus need 
training for production 
employees 
Knowledge transfer from 
RC to HC 
Knowledge transfer from 
SC to RC 
Knowledge transfer from 
HC to SC 
The part of marketing to 
give feedback about the 
quality of med rep when 
doing presentations with the 
doctor, and also the quality 
of the sales team 
The part of operational to 
provide training on new 
technology used for drug 
database system and also 
customer of companies 
Senior manager gives 
explanation about the 
organizational strategy 
purpose plan 
Source: Managed Data 
At this stage, KM with SECI concept is also highly acceptable for the key 
informants. According to key informants, the SECI process is very well in the context of 
knowledge sharing and knowledge transfer as well as change from tacit knowledge to 
explicit knowledge and vice versa. According to the informant, SECI with the process of 
socialization, externalization, combination, internalization is able to accelerate the 
process of change of the knowledge either tacit knowledge or explicit knowledge. With 
the acceleration of knowledge transfer and knowledge sharing that will certainly 
accelerate the support for the performance of the company or organization. 
Socialization process changes from tacit knowledge to tacit knowledge. It is often 
called the brainstorming, it is tools used to share the idea of every member of the team 
that carried out structured and systematically. The key of success of a brainstorming 
session is a free atmosphere without criticism to explore creative ideas in order to obtain 
an alternative solution without limits. Some of the benefits of brainstorming are: 
13 
 
a. Improve the creativity and produce many ideas in short time, with expanding the 
perspective from every aspect or thought of team member who will share another idea 
in ourselves, 
b. Create the equality against all team involved in brainstorming process, the warm 
atmosphere and support each other, and without critic will encourage someone to feel 
comfortable to share the idea without any obstruction. It will cause the mutual 
respect, 
c. When every team member shares his/ her idea, then the team member will be 
involved and will support the decision making direction, it will grow a sense of 
belonging to the process. 
According to the informant, that socialization process often happens in the 
pharmaceutical company even the time has been scheduled. It can be every week or 
at any time depending on the needs of each department. Brainstorming on the 
pharmaceutical company's marketing department, for example, is more about how 
to design an effective and telling marketing system, including how they handle the 
customers’ or doctors’ complaints. This customers’ complaints is typically 
associated with OTC (on the counter) drugs or ethical drugs. For example, the 
packaging is easily damaged, competitor's products are more preferable, and others. 
Things like that are often discussed in the form of brainstorming by converting tacit 
knowledge to tacit knowledge. 
Externalization process, it is changing tacit knowledge into explicit knowledge. 
According to the informants this is done by changing seniors’ knowledge in the form of 
know-how into the recorded fixed rule. So the core of this process is to make things into 
written knowledge that is recorded. For example, the ability ofmedical representative to 
negotiate with the doctor. Or the ability of tacit knowledge possessed by pharmacists 
related to the fulfillment of CPOB policy of Food and Drugs Monitoring Agency of 
Republic of Indonesia (BPOM RI). With the wide range of knowledge that is recorded 
will be very useful for other employees who need it and for the sustainability of 
pharmaceutical companies. 
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Combination process is done when explicit knowledge is changed or implemented 
to other explicit knowledge. According to key informants, it often happens during CPOB 
implementation from BPOM RI changed into standard operational procedure (SOP) of 
production or operational in the pharmaceutical company. Also, when the 
pharmaceutical company send their employee to the training or college, he/she must be 
able to make system breakthrough or effective working procedure in the form of 
recorded SOP. This process is highly effective to improve skill and productivity of the 
employees. This example shows that the connecting and combining of explicit 
knowledge into new explicit knowledge is more useful. 
Internalization process happens when explicit knowledge is changed into tacit 
knowledge. Other terms are contemplation. It is done by changing explicit knowledge in 
the form of SOP, working procedure, or other regulation that have been recorded into 
invisible knowledge in the form of ideas and also another material that will be developed 
and still in the thought of the employee. For example, pharmaceutical product from other 
factories as competitor is discussed with employee to make better product so that the 
product can be competitive. It is called internalization. 
 
2. Innovation Management Stage 
At this IM stage, innovation strategy comes from four things, namely customer 
driven (from customer), inward employee driven (from inside of employee), outward 
employee driven (from outside of employee), and technology driven (from technology). 
According to the key informants, innovation source often come from customer driven 
(from customer). The following on order are from the inside of employee (inward 
employee), from outside of employee (outward employee), and from technology 
(technology driven). 
The informant also stated that the innovation of pharmaceutical product (OTC 
drugs) comes from customer and competitor. Therefore, customers deliver to 
pharmaceutical sales worker and then delivered to marketing manager. And then 
marketing manager will discuss it in the meeting among the managers or even in its 
marketing director. Innovation can also come from creative employee or employee who 
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followed the training. Thus, the gained knowledge from the training will be delivered as 
new idea. Meanwhile, innovation can also come from outside of employee, for example 
from management, from shareholder, from owner and others. For innovation from 
technology, it is usually due to emergency requirement of a machine or equipment that is 
required in CPOB and company shall purchase it or because the machine, equipment or 
computer has been out of date. 
Meanwhile, related to the stages of CICM and management objectives, key 
informants gave the opinion that the pharmaceutical companies in this IM stages have 
started to find the innovation resources, so that they can begin to create new ways and 
new products faster. Pharmaceutical companies in this stage had started (sorted) out of 
the internal management issues. That is to say, the internal management is well defined 
so that it can start to move "out" and do new ways which are more innovative and 
creative. Innovation source of pharmaceutical companies is more than the marketing 
teams who see the market condition as well as from the employees. All IC components, 
namely HC, SC and RC support the creation of efforts for innovation and creativity. HC 
has begun to develop and empower all knowledge, experience, and skills they have to 
create new things and new creations. SC also supports the creation of innovation to start 
the growth of a culture of innovation and provides wide opportunity to HC for 
innovation and creativity. Systems and working procedures also provide an opportunity 
for employees to dare to try new things for the new ways which are more innovative and 
faster. Likewise, the RC has begun to capture the wishes and market changes including 
consumers’ behavior, so that they can provide innovation input to the company 
management. 
3. Intellectual Property Management Stage 
At this IPM stage, pharmaceutical company can conduct intellectual wealth 
management by brand management (the existence of special work unit to handle brand 
of the company) and IP portfolio (improve good IP, combine good IP with the bad one, 
and eliminate IP which is already gone in the market). Related to brand management, 
according to the informants, there should be a special unit or department that handles IP 
in the pharmaceutical companies, since there has not been such units or departments in 
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those companies. Usually, such units are only included in the department marketing that 
monitors the movement of each drug product. Meanwhile, for the IP portfolio indeed it 
is done in various combinations in practice. It is by monitoring the medicinal products 
which are already slow-moving or still fast moving. If the drug has begun to slow-
moving, the pharmaceutical companies think and act so that the product could rise again. 
For example, by adding flavor with orange or strawberry flavor for pharmaceuticals 
children. Another thing to do is to change or improve the product packaging so it looks 
new and favored by customers. In some pharmaceutical companies, drug advertising star 
also becomes a determinant of the success of the drug. For example headache medicine 
Oskadon starred by Manteb Sudarsono, a famous puppeteer in Indonesia. However, as 
well as the behavior of commercials star, if the star has bad behavior and meet his doom 
with negative publicity in the media, the sale will be affected as well. Thus, a 
pharmaceutical company will replace the commercials star. 
Meanwhile, related to the stages of CICM and objectives of management, as in 
Figure 1 and Table 4, the informant gave the opinion that the pharmaceutical companies 
in this stage already have intellectual property, such as the brand of products has begun 
to emerge, the brand image of the company is also known, including the leader product 
of the company. The existence of a variety of intellectual property, pharmaceutical 
companies is able to earn income (superiorprofit) and also able to increase the 
company's competitive position. At this stage, the intellectual property owned by 
pharmaceutical companies are not only associated with the drug, but already on other 
aspects. It means that many pharmaceutical companies have diversified their products or 
do many business conglomerations. Diversification of medicinal products is carried out 
by making products such as immunity, dairy, food and beverage supplements, and also 
healthy drinks. The point is that the products should support health. Pharmaceutical 
companies do business conglomerations with other businesses that are still related to 
pharmaceuticals and drugs, such as making dispensaries or making health clinics. There 
was even an effort to make the pharmaceutical business conglomerations from upstream 
to downstream, for example by building a factory of  bag or wrapping manufacturers of 
drugs, intravenous tubes, bags of capsules and other pharmaceutical preparations. 
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Pharmaceutical companies that own intellectual property will be easier to compete and 
gain revenue. Leader product or a branded product which is very beneficial for the 
pharmaceutical companies because the products are more easily remembered by the 
community, for example when have headache, people will always remember Bodrex or 
Oskadon. Brand images also greatly affect the public perception, for example products 
of Kalbe Farma must be good, or Kimia Farma pharmacy is certainly complete. Things 
like this are called intellectual property. 
Thus the existence of CICM model consists of three stages, namely knowledge 
management, innovation management, and intellectual property management can be 
complement of RTB and KBT role. The definition of complement of the role is CICM 
model as management model that is able to technically operationalize the integration of 
IC and KM with RBT and KBT as the principle theory. 
 
Conclusion and Suggestion 
Based on the research result that has been done, the research conclusion is the 
integration concept of IC and KM that can improve and renew RBT and KBT as principle 
theory of IC and KM must be adjusted with existing industrial condition or pharmaceutical 
company in Indonesia. By considering the pharmaceutical company condition in Indonesia 
that not all pharmaceutical company can be categorized as high IC intensive. Thus 
pharmaceutical companies in Indonesia still need the role of tangible assets even though in 
some pharmaceutical companies the role of tangible assets is more than intangible assets. 
Based on the result, this research result is partially changed with the initial research plan 
that is not to improve or renew RBT and KBT but more to complement the role of those 
theories. The management model used to complement the role of RBT and KBT is CICM 
model because it is very complete and comprehensive and as the integration or combination 
of IC and KM. 
Meanwhile, the advice in this research is for the managers of pharmaceutical 
companies who should be able to understand IC, KM, and business performance and its 
components respectively. This is important because the interaction between the components 
of IC and KM can improve performance either partially or simultaneously. The managers 
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of a pharmaceutical company in Indonesia also have to understand about the two models of 
integration of IC and KM. Two models of integration are intended for pharmaceutical 
companies which are new with the first model and the second model when the 
pharmaceutical companies have started during the development stage. The two models can 
be utilized by pharmaceutical companies. 
It is suggested further research to conduct mapping research of pharmaceutical 
companies which are high IC intensive or non high IC intensive so that the research results 
of IC in the Indonesian pharmaceutical company can be optimized. This is important 
because the condition of industrial or pharmaceutical company in Indonesia is different 
from foreign pharmaceutical companies which are used by researchers IC overseas. While 
many domestic IC researchers which previous reference research from abroad. Obviously 
with the IC research result, the domestic IC researchers can be more careful in determining 
the object of research. 
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